Hormone Therapy for Dogs and Cats Requires Species-Specific Monitoring, Not a Shared Treatment Plan
A new diagnosis of an endocrine disorder often arrives with relief and confusion in the same breath. The relief comes from finally having an explanation for months of subtle changes — a dog's thinning coat, a cat's sudden weight loss despite a ravenous appetite. The confusion comes next, usually while reading about pet hormone replacement treatment monitoring for dogs and cats and discovering that almost nothing about one species' protocol applies to the other. That distinction is not a technicality. Canine and feline endocrine disease sit on nearly opposite ends of the hormone spectrum, and the bloodwork schedule, drug class, and warning signs that matter for a hypothyroid Labrador have little overlap with what matters for a hyperthyroid cat starting methimazole. Understanding which category your pet falls into, and what monitoring that category actually demands, is the real starting point.
Dogs and Cats Get Different Endocrine Diseases for a Reason
It surprises many owners the first time they hear it: dogs and cats tend to develop opposite thyroid problems. Middle-aged and senior dogs are disproportionately prone to hypothyroidism, a state of hormone deficiency usually caused by autoimmune destruction of the thyroid gland, and they're also the species where Cushing's disease — excess cortisol production — shows up with any frequency. Cats, by contrast, are far more likely to develop hyperthyroidism, driven in most cases by a benign thyroid nodule producing too much hormone rather than too little.
Neither pattern is random. Canine thyroid tissue and feline thyroid tissue age differently, and the metabolic pathways that regulate cortisol and thyroid hormone diverge enough between species that a drug correcting a deficiency in one animal would be actively dangerous if given to an animal with the opposite problem. This is why hormone medications must never be shared or repurposed across species or even across pets of the same species without an individual diagnosis. A dose of levothyroxine that stabilizes one dog's thyroid says nothing about what another dog, or any cat, actually needs.
Diabetes is the exception that shows up in both species, but even there the physiology and insulin protocols differ enough that a feline diabetic's regulation plan isn't interchangeable with a canine one. What all of these conditions share is a dependence on lifelong, monitored hormone or insulin therapy rather than a one-time fix.
Canine Endocrine Disease: Hypothyroidism and Cushing's Follow Their Own Monitoring Rules
For dogs, the two conditions that dominate endocrine caseloads are hypothyroidism, treated with synthetic levothyroxine, and Cushing's disease (hyperadrenocorticism), typically managed with trilostane. Both require monitoring that isn't optional, and both have a monitoring rhythm that looks completely different from what a hyperthyroid cat undergoes.
Levothyroxine dosing is usually reassessed a few weeks after starting therapy or after any dose change, with blood drawn several hours after the pill to check the peak hormone level, according to veterinary endocrinology guidance from the American Animal Hospital Association. Once the dose is stable, most dogs move to a check every six to twelve months. Trilostane for Cushing's disease follows an even tighter early schedule: an ACTH stimulation test — which measures how the adrenal glands respond to a stimulating hormone before and after a cortisol-suppressing injection — is typically performed within the first couple of weeks of starting the drug and again after dose adjustments, because trilostane's effect on cortisol production can shift quickly and unpredictably in some dogs.
The clinical blind spot with trilostane isn't usually underdosing. It's the dog that looks fine on the outside while cortisol suppression quietly overshoots into iatrogenic hypoadrenocorticism — a drug-induced version of Addison's disease that can escalate to a life-threatening Addisonian crisis if a scheduled recheck is skipped or delayed.
Addison's disease itself, whether naturally occurring or drug-induced, is why abrupt cessation of any adrenal-affecting hormone therapy is treated as a genuine emergency risk rather than a minor inconvenience. A dog that suddenly stops receiving trilostane, or one whose adrenal function has been suppressed too far, can develop vomiting, collapse, and dangerously low blood pressure within a short window.
Feline Endocrine Disease: Hyperthyroidism and Diabetes Demand a Different Rhythm
Cats on methimazole for hyperthyroidism follow a monitoring timeline built around total T4 testing roughly two to four weeks after starting or adjusting the dose, then extending to every three to six months once the cat is stable, consistent with consensus guidance from the International Society of Feline Medicine and AAHA's feline endocrinology recommendations. Bloodwork at these visits typically checks more than thyroid levels alone — kidney values and a complete blood count matter too, because hyperthyroidism can mask underlying kidney disease, and methimazole itself carries a recognized risk of bone marrow effects and liver enzyme changes in the first several months of treatment.
Radioactive iodine therapy is the one hormone-related intervention in this entire discussion that can function as something closer to a permanent fix for feline hyperthyroidism rather than a lifelong daily medication, though it's a specialized procedure performed at select facilities and isn't the default first-line option for every cat.
Feline diabetes runs on an entirely separate monitoring framework centered on insulin, not thyroid hormone. Regulation is typically assessed through blood glucose curves and fructosamine testing, a marker that reflects average blood sugar control over roughly the prior two to three weeks rather than a single moment in time. According to AAHA's diabetes management guidelines, any change to an insulin dose should be followed by a glucose curve within one to two weeks to confirm the adjustment is working as intended, since insulin has almost no safety margin for guesswork.
Here's how the two major feline conditions compare at a glance:
Why Therapeutic Drug Monitoring Isn't a Formality
It's tempting to think of the recheck bloodwork as a routine box to check, especially once a pet seems to be doing well on medication. Therapeutic drug monitoring exists precisely because "seems fine" and "is correctly dosed" are not the same thing with hormone therapy. Thyroid hormone, cortisol, and insulin all operate on feedback loops with narrow effective ranges, and a dose that was correct three months ago can become too high or too low as a pet's weight changes, kidney function shifts, or the underlying disease progresses.
This is also where owner expectations sometimes clash with the reality of chronic disease management. A cat whose appetite returns and coat improves on methimazole isn't necessarily at an optimal T4 level; the dose might still need fine-tuning based on lab numbers rather than appearance alone. The same is true of a dog on trilostane that looks energetic — cortisol suppression can be subclinical until it isn't. Skipping a recheck to save a visit, or adjusting a dose based on how a pet looks rather than what a test shows, removes the only reliable safeguard against both under- and overtreatment.
Recognizing When a Pet Needs Urgent Care, Not a Wait-and-See Approach
Certain signs during hormone or insulin therapy shouldn't wait for the next scheduled appointment. In diabetic dogs and cats, disorientation, wobbliness, seizures, or collapse can indicate dangerously low blood sugar from an insulin dose that's too high relative to food intake, and this can progress quickly. On the opposite end, a diabetic pet that suddenly stops eating, vomits repeatedly, or becomes profoundly lethargic may be developing diabetic ketoacidosis, a metabolic crisis that needs emergency veterinary treatment rather than home monitoring.
In dogs on trilostane, sudden vomiting, diarrhea, severe lethargy, or collapse can point to iatrogenic hypoadrenocorticism progressing toward an Addisonian crisis, particularly if a dose was recently increased or if a scheduled ACTH stimulation recheck was missed. Any pet showing pale gums, labored breathing, or an inability to stay conscious needs emergency assessment immediately, regardless of which hormone condition is being managed. None of these situations are appropriate for adjusting a dose at home first; they call for a veterinarian or emergency clinic directly.
The Honest Limits of Hormone Therapy
With the exception of radioactive iodine for some hyperthyroid cats, hormone and insulin therapies for these conditions manage the disease rather than cure it. That distinction matters for expectations: a dog stabilized on levothyroxine will typically need it for life, and stopping the medication without veterinary guidance risks the hypothyroid symptoms returning, sometimes gradually enough that owners don't immediately connect the decline to the missed doses. Supportive products, joint or coat supplements, and general wellness care can be reasonable additions to an endocrine care plan, but they aren't substitutes for the hormone or insulin therapy itself, and none of them correct thyroid, adrenal, or insulin deficiencies on their own.
Rigid daily dosing matters more with these medications than with almost any other category of veterinary drug, because the feedback loops involved don't tolerate skipped doses or "catch-up" doubling well. A missed dose of trilostane or insulin isn't something to compensate for by giving extra at the next scheduled time without specific veterinary instruction, since that approach can overshoot into the same overdose territory the monitoring schedule is designed to prevent.
Owners newly navigating one of these diagnoses sometimes start by comparing supportive product categories before their pet's baseline labs are even finalized, which understandably creates pressure to decide too early. Reviewing endocrine support products can be a reasonable way to understand what general category of support exists alongside prescribed hormone therapy, though any product intended to sit alongside levothyroxine, trilostane, methimazole, or insulin should be discussed with the prescribing veterinarian first, particularly given how sensitive these feedback systems are to any added variable.
Frequently Asked Questions
How often does my pet need bloodwork while on hormone therapy? It depends on the condition and how recently the dose changed — early treatment typically means rechecks every two to six weeks, while a stable pet on an established dose usually moves to testing every three to twelve months, with the exact interval set by the prescribing veterinarian based on lab trends.
Are hormone treatments for pets lifelong? In most cases yes; conditions like canine hypothyroidism, canine Cushing's disease, and feline diabetes are managed rather than cured, while feline hyperthyroidism is the main exception where radioactive iodine can sometimes eliminate the need for ongoing medication.
Understanding the general shape of these protocols can make conversations with a veterinarian more productive, but the specific dose, testing interval, and drug choice always depend on an individual pet's diagnosis, lab trends, and response to treatment. For pet owners who want a broader look at how veterinary guidelines shape chronic-care decisions beyond endocrine disease, it can help to read about veterinary medical guidelines as a starting point before the next scheduled recheck.